Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study

The Lancet Oncology

Volumn 18, Issue 1, 2017, Pages 112-121

  Gillis, Nancy K ^a,b   Ball, Markus ^a   Zhang, Qing ^a   Ma, Zhenjun ^a   Zhao, YuLong ^a   Yoder, Sean J ^a   Balasis, Maria E ^a   Mesa, Tania E ^a   Sallman, David A ^a   Lancet, Jeffrey E ^a   Komrokji, Rami S ^a   List, Alan F ^a   McLeod, Howard L ^a   Alsina, Melissa ^a   Baz, Rachid ^a   Shain, Kenneth H ^a   Rollison, Dana E ^a   Padron, Eric ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTITUBULIN AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUOROURACIL; GYRASE INHIBITOR; MELPHALAN; MITOMYCIN; OXALIPLATIN; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE; TUMOR MARKER;

ACUTE MYELOID LEUKEMIA; AGED; ANUS CARCINOMA; ARTICLE; BIOBANK; BLOOD SAMPLING; BONE MARROW CANCER; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; CLONAL EVOLUTION; CLONAL HAEMOPOIESIS OF INDETERMINATE POTENTIAL; CLONE; COLORECTAL CARCINOMA; CONCEPTUAL FRAMEWORK; CONTROLLED STUDY; DIAGNOSTIC TEST; DIFFUSE LARGE B CELL LYMPHOMA; DRUG SAFETY; ESOPHAGEAL ADENOCARCINOMA; FEMALE; FLORIDA; FOLLICULAR LYMPHOMA; FOLLOW UP; GENE MUTATION; GENETIC TRAIT; HEMATOPOIESIS; HIGH RISK PATIENT; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEIOMYOSARCOMA; LUNG ADENOCARCINOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUROENDOCRINE TUMOR; PREVALENCE; PRIMARY TUMOR; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; WHOLE EXOME SEQUENCING; CANCER STAGING; CASE CONTROL STUDY; CELL CLONE; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG EFFECTS; GENETICS; HIGH THROUGHPUT SEQUENCING; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; PATHOLOGY; PROCEDURES; PROGNOSIS; RISK FACTOR; SURVIVAL RATE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CLONE CELLS; FEMALE; FLORIDA; FOLLOW-UP STUDIES; HEMATOPOIESIS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; NEOPLASM STAGING; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 85007496735     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30627-1     Document Type: Article

References (31)

1. 1 Morton, LM, Dores, GM, Tucker, MA, et al. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975–2008. Blood 121 (2013), 2996–3004.
2. 2 Malmgren, JA, Calip, GS, Pyott, SM, Atwood, MK, Kaplan, HG, Therapy-related myelodysplastic syndrome following primary breast cancer. Leuk Res 47 (2016), 178–184.
3. 3 Ben-Yehuda, D, Krichevsky, S, Caspi, O, et al. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood 88 (1996), 4296–4303.
4. 4 Shih, AH, Chung, SS, Dolezal, EK, et al. Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia. Haematologica 98 (2013), 908–912.
5. 5 Godley, LA, Larson, RA, Therapy-related myeloid leukemia. Semin Oncol 35 (2008), 418–429.
6. 6 Wong, TN, Ramsingh, G, Young, AL, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 518 (2015), 552–555.
7. 7 Genovese, G, Kahler, AK, Handsaker, RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 371 (2014), 2477–2487.
8. 8 Jaiswal, S, Fontanillas, P, Flannick, J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371 (2014), 2488–2498.
9. 9 Steensma, DP, Bejar, R, Jaiswal, S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126 (2015), 9–16.
10. 10 Fenstermacher, DA, Wenham, RM, Rollison, DE, Dalton, WS, Implementing personalized medicine in a cancer center. Cancer J 17 (2011), 528–536.
11. 11 Li, H, Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. https://arxiv.org/pdf/1303.3997v2.pdf (accessed Sept 20, 2016).
12. 12 Li, H, Handsaker, B, Wysoker, A, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25 (2009), 2078–2079.
13. 13 Garrison, E, Gabor, M, Haplotype-based variant detection from short-read sequencing. https://arxiv.org/pdf/1207.3907v2.pdf (accessed Sept 20, 2016).
14. 14 Saunders, CT, Wong, WS, Swamy, S, Becq, J, Murray, LJ, Cheetham, RK, Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 28 (2012), 1811–1817.
15. 15 Danecek, P, Auton, A, Abecasis, G, et al. The variant call format and VCFtools. Bioinformatics 27 (2011), 2156–2158.
16. 16 Wang, K, Li, M, Hakonarson, H, ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res, 38, 2010, e164.
17. 17 Miller, CA, White, BS, Dees, ND, et al. SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput Biol, 10, 2014, e1003665.
18. 18 Papaemmanuil, E, Gerstung, M, Malcovati, L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122 (2013), 3616–3627.
19. 19 Kayser, S, Dohner, K, Krauter, J, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 117 (2011), 2137–2145.
20. 20 Giordano, SH, Duan, Z, Kuo, Y-F, Hortobagyi, GN, Goodwin, JS, Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 24 (2006), 2750–2756.
21. 21 DeMichele, A, Putt, M, Zhang, Y, Glick, JH, Norman, S, Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma. Cancer 97 (2003), 2150–2159.
22. 22 Gross, CP, McAvay, GJ, Guo, Z, Tinetti, ME, The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer. Cancer 109 (2007), 2410–2419.
23. 23 Coates, AS, Winer, EP, Goldhirsch, A, et al. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 26 (2015), 1533–1546.
24. 24 Dienstmann, R, Salazar, R, Tabernero, J, Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. J Clin Oncol 33 (2015), 1787–1796.
25. 25 Takahashi, K, Wang, F, Kantarijian, H, et al. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol, 2016 published online Dec 3. http://dx.doi.org/10.1016/S1470-2045(16)30626-X.
26. 26 Zehir, A, Coombs, CC, Devlin, S, et al. Prevalence of clonal hematopoiesis in patients with advanced cancer. Proc Am Soc Clin Oncol, 34(suppl), 2016 abstr 1511.
27. 27 Ruark, E, Snape, K, Humburg, P, et al. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature 493 (2013), 406–410.
28. 28 Young, AL, Challen, GA, Birmann, BM, Druley, TE, Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun, 7, 2016, 12484.
29. 29 Voso, MT, Fabiani, E, Zang, Z, et al. Fanconi anemia gene variants in therapy-related myeloid neoplasms. Blood Cancer J, 5, 2015, e323.
30. 30 Knight, JA, Skol, AD, Shinde, A, et al. Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. Blood 113 (2009), 5575–5582.
31. 31 Chakraborty, S, Sun, CL, Francisco, L, et al. Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J Clin Oncol 27 (2009), 791–798.